Physician profile
Thomas Martyak
NPI 1285621003
$66,386.25
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $9,658 · 2021: $13K · 2022: $639 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $49,276.90 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13,545.40 | 2019-2022 | |
| Irhythm Technologies, INC. | $845.67 | 2019-2021 | |
| Amgen INC. | $341.54 | 2019-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $331.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $327.95 | 2019-2021 | |
| Esperion Therapeutics, INC. | $181.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $169.21 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.65 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.98 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $142.41 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $125.76 | 2019 | |
| Chiesi USA, INC. | $104.21 | 2020 | |
| Novartis Pharmaceuticals Corporation | $90.46 | 2019-2021 | |
| Astellas Pharma US INC | $89.37 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $81.57 | 2021 | |
| Allergan, INC. | $57.03 | 2019 | |
| Nuwellis, INC. | $54.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $54.36 | 2019 | |
| Cardiva Medical, INC. | $36.63 | 2019-2020 | |
| United Therapeutics Corporation | $30.47 | 2019 | |
| Pfizer INC. | $26.11 | 2019 | |
| Medicomp INC | $23.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.42 | 2019 | |
| Novo Nordisk INC | $18.65 | 2020 | |
| Merck Sharp & Dohme LLC | $14.70 | 2021 | |
| Boston Scientific Corporation | $14.48 | 2019 | |
| Lundbeck LLC | $14.39 | 2019 | |
| Medtronic Vascular, INC. | $14.27 | 2019 | |
| Penumbra, INC. | $13.41 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.79 | 2019 | |
| Gilead Sciences, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Martyak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.